MeMed
Israel’s MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
MeMed announced Monday a $93 million private financing round, bringing total funding in the company to over $200 million, including support from the U.S. Department of Defense and EU Commission. The funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio, The latest…
